Cytodyn is a 9-year old biotech startup nearing FDA approval for Leronlamib, a humanized monoclonal antibody that's shown no side effects with over 800 AIDS patients through a Phase 3 HIV combo-therapy trial. But Leronlamib is also showing broad efficacy in early trials for HIV monotherapy, HIV prevention, blocking metastasis of many cancers, graft vs host disease, and fatty liver disease (NASH). It was tremendously undervalued until mid-December when it signed an $87 million HIV licensing and commercialization that has stabilized its financing and launched price in a strong up-channel. Submission of BLA application to FDA for HIV combo therapy is imminent in January, which should allow for FDA approval and first sales in 2020. Leronlamib has the potential to transform treatment of several major diseases. Disclosure: I am heavily long.